Monitoring cancer treatment with PET/CT: does it make a difference?
about
Optimisation of whole-body PET/CT scanning protocolsTranslational imaging endpoints to predict treatment response to novel targeted anticancer agents.ELIXYS - a fully automated, three-reactor high-pressure radiosynthesizer for development and routine production of diverse PET tracers.Ultra-low dose CT attenuation correction for PET/CT: analysis of sparse view data acquisition and reconstruction algorithms.PET/CT in Oncology: Current Status and Perspectives.Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumorsA phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trialFrom RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.Proteomic and metabolic prediction of response to therapy in gastric cancer.Functional imaging in lung cancerSUVref: reducing reconstruction-dependent variation in PET SUV.The future of hybrid imaging-part 2: PET/CT.Accurate dispensing of volatile reagents on demand for chemical reactions in EWOD chips.Imaging of lung cancer in the era of molecular medicineDoes early PET/CT assesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer?Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials.Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy.Improved Benefit of SPECT/CT Compared to SPECT Alone for the Accurate Localization of Endocrine and Neuroendocrine Tumors.MIBG molecular imaging for evaluating response to chemotherapy in patients with malignant pheochromocytoma: preliminary results.Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck.First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy.Effects of ROI Placement on PET-Based Assessment of Tumor Response to Therapy.Image reconstruction for PET/CT scanners: past achievements and future challenges.PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients.Chemotherapy-induced modulation of [18F]Fluoro-2-deoxy-D-glucose incorporation at the tumour cell level.
P2860
Q28744472-AC3B34CD-7096-441F-AD49-40BF8339C439Q30465097-596B739A-74AB-44F6-956B-B19EB099010DQ30541618-44BCCD38-5A9B-44C5-A0A2-F00DC2BF3BCDQ30992320-5E2797C9-6654-42EA-8A9F-BC111F0473CDQ33665109-67695D1A-C6EF-4436-AFAC-434B9E4C6A4CQ33806271-D59650D8-C68D-4A44-A815-83874C74E4B8Q34206726-6AA1D9EE-4493-44DC-BD27-6661926C61D0Q34978457-40FF7193-E95C-47DA-9223-0BCB1DBAB405Q35336183-E2472E4F-1A9A-435C-BAED-F74243CC196EQ35550676-664C8708-AFA2-4E52-9192-B84CF0DC6841Q35650639-A796A467-77C7-4A93-A118-C1201849B82EQ35786046-077E7D01-33C2-4446-B161-CB33F2F81F15Q35811542-56F6AEC0-ED7E-41B2-8390-92C96EA0FC04Q36050371-7D99C6CF-7277-4DE4-B97A-4E12302C1AB5Q36154024-FDBF65F2-A1C1-44B4-97DE-BD305C906E13Q36303559-8D43C80A-9AD3-4DD4-91B8-D37AD67385F3Q36429530-4733C379-B77F-46CC-A3DF-671DE3C9DCCBQ36508524-351EA807-8E32-471E-8E4C-D36BFF568358Q36664675-8A03E04D-0F5B-424C-A2C1-F165B79314B5Q36776978-391929AA-7EBA-4814-9E68-77F3CB57ED0EQ37170947-7DC66FE5-BCA8-441B-B7FC-1217032FA0A2Q37433474-DF875DCD-FEBC-4F12-87EE-D58DB742BCF9Q38965447-46B88DBF-4BF5-4D82-8925-5EFD2C6803DEQ39245990-0355EA57-82D0-46A2-8929-A5106D1C0166Q39780317-7DF5306D-16BC-46B5-B6A9-95A4B041B00FQ42721856-445E3914-CEE1-41D9-8746-08954EB4305FQ46943359-41731D0E-6AC4-4A83-BC7E-B4A2D59F6C54
P2860
Monitoring cancer treatment with PET/CT: does it make a difference?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Monitoring cancer treatment with PET/CT: does it make a difference?
@ast
Monitoring cancer treatment with PET/CT: does it make a difference?
@en
type
label
Monitoring cancer treatment with PET/CT: does it make a difference?
@ast
Monitoring cancer treatment with PET/CT: does it make a difference?
@en
prefLabel
Monitoring cancer treatment with PET/CT: does it make a difference?
@ast
Monitoring cancer treatment with PET/CT: does it make a difference?
@en
P1476
Monitoring cancer treatment with PET/CT: does it make a difference?
@en
P2093
Robert Figlin
Wolfgang A Weber
P304
P407
P478
48 Suppl 1
P577
2007-01-01T00:00:00Z